Navigation Links
Trubion Pharmaceuticals to Present at Upcoming Investor Conferences

Dr. Peter Thompson to Present at BioCentury's Newsmakers in the Biotech Industry, Bank of America Investment, and UBS Global Life Sciences Investor


SEATTLE, Sept. 4 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that Dr. Peter Thompson, president, chief executive officer, and chairman of Trubion, will present an overview of the company at three September investor conferences:

-- BioCentury's NewsMakers in the Biotech Industry conference at the

Millennium Broadway Hotel & Conference Center, 145 W. 44th St., New

York. Dr. Thompson is scheduled to present on Thursday, Sept. 6. A

webcast of the presentation will be available at 70.

-- Bank of America 37th Annual Investment Conference at the Ritz-Carlton,

600 Stockton St. (at California St.), San Francisco. Dr. Thompson is

scheduled to present on Monday, Sept. 17. A webcast of the presentation

will be available at

-- UBS Global Life Sciences Investor Conference at the Grand Hyatt, 109 E.

42nd St. (at Grand Central Station), New York. Dr. Thompson is

scheduled to present on Monday, Sept. 24. A webcast of the presentation

will be available at

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP(TM) custom drug assembly technology. In less than 24 months the Company designed, developed and submitted to the FDA an Investigational New Drug application for, its lead product candidate, TRU-015, which has completed a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Subject to satisfactory completion of preclinical testing of TRU-016, the company expects to file an IND for TRU-016 in the second half of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
Breaking Biology Technology:
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
Breaking Biology News(10 mins):